


June 6, 2022



## PAXLOVIDTM FOR A PATIENT ON A DOAC DIRECT ORAL ANTICOAGULANT


who is also at high risk of hospitalization from COVID-19 (e.g., unvaccinated or immunocompromised)



## \*Decisions to hold, adjust, or change medications should be made on a patient-specific basis.







 People who take a DOAC should stay up to date with their COVID-19 vaccines, including boosters.

It can be challenging to manage drug interactions between COVID-19 treatments and DOACs. Vaccination can reduce the risk of needing treatment for COVID-19.

Contributors: Kelly Grindrod, BScPharm, PharmD, MSc. Claudia Bucci, BScPhm, PharmD, ACPR. Stephanie Carlin, PharmD, ACPR2. Andrea Chittle, MD, CCFP, Noah Ivers, MD, PhD, CCFP, Heather Kertland, PharmD, FCSHP. Tara Kiran, MD, MSc, CCFP, FCFP. Kori Leblanc, BScPhm, PharmD, ACPR. Catia Marzolini, PharmD, PhD. Kate Miller, MD, CCFP, FCFP. Menaka Pai, MSc, MD, FRCPC. Adrian Poon, BA. Alice Tseng, PharmD, FCSHP, AAHIVP. Kristen Watt, BScPhm, RPh. Samira Jeimy, MD, PhD, FRCPC. Reviewed by: Rosemary Killeen, BScPhm, PGCert, RPh.

Financial contribution from:



